Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

M, Gnant; B, Mlineritsch; W, Schippinger; G, Luschin-Ebengreuth; S, Pöstlberger; C, Menzel; R, Jakesz; M, Seifert; M, Hubalek; V, Bjelic-Radisic; H, Samonigg; C, Tausch; H, Eidtmann; G, Steger; W, Kwasny; P, Dubsky; M, Fridrik; F, Fitzal; M, Stierer; E, Rücklinger; R, Greil; C, Marth

doi:10.1056/nejmoa0806285

Public

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Shared by NobleBlocks on Feb 1, 2009 • 12:00 AM UTC

Authors:

Gnant M

Mlineritsch B

Schippinger W

Abstract

<h4>Background</h4>Ovarian suppression plus tamoxifen is a standard adjuvant treatment in premenopausal women with endocrine-responsive breast cancer. Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclinical data suggest that zoledronic acid has antitumor properties...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!